The latest I heard
was that Teva has petitioned
A to require new phase 2 d
pahse 3 stud
ies for the d
ae8f4'>copaxone generics "since the process d
formulation of the generics hsa not been proven to be as safe or as clinically effective as the Teva formulation." There is a several million d
ollar hit ot getting a generic to market.
"Teva is pulling out all the stops to protect d
ae8f4'>copaxone, which provid
es 25%-33% of the pharmaceutical company's profit.